• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Clinical and Molecular Allergy : CMA >Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
【2h】

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis

机译：5-草花粉片舌下免疫疗法治疗季节性变应性鼻炎的药物经济学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Allergic rhinitis has a very high burden regarding both direct and indirect costs. This makes essential in the management of AR to reduce the clinical severity of the disease and thus to lessen its costs. This particularly concerns allergen immunotherapy (AIT), that, based on its immunological action on the causes of allergy, extends its benefit also after discontinuation of the treatment. From the pharmacoeconomic point of view, any treatment must be evaluated according to its cost-effectiveness, that is, the ratio between the cost of the intervention and its effect. A favorable cost-benefit ratio for AIT was defined, starting from the first studies in the 1990s on subcutaneous immunotherapy (SCIT) in AR patients, that highlighted a clear advantage on costs over the treatment with symptomatic drugs. Such outcome was confirmed also for sublingual immunotherapy (SLIT), that has also the advantage on SCIT to be free of the cost of the injections. Here we review the available literature on pharmacoeconomic data for SLIT with the 5-grass pollen tablets.
机译：过敏性鼻炎在直接和间接费用方面都有很高的负担。这对于减少AR的临床严重性并因此降低其成本在AR的管理中至关重要。这尤其涉及变应原免疫疗法（AIT），基于其对过敏原因的免疫作用，在治疗中断后也能扩大其益处。从药物经济学的观点来看，任何治疗都必须根据其成本效益进行评估，即干预成本与其效果之间的比率。从1990年代关于AR患者皮下免疫疗法（SCIT）的第一项研究开始，就定义了AIT的有利成本效益比，这突显了成本高于对症药物的明显优势。舌下免疫疗法（SLIT）也证实了这种结果，这在SCIT上也有优势，无需注射费用。在这里，我们回顾了有关5草粉花粉片SLIT的药物经济学数据的可用文献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号